Simulated cost ‐effectiveness of a novel precision‐guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy

ConclusionsPGD provides clinical and QoL benefits by maintaining remission and avoiding IFX failure; it is the most cost-effective under conservative assumptions.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 5, 2024 Category: Drugs & Pharmacology Authors: Elmar R. Alizadeh, Thierry Dervieux, Severine Vermeire, Marla Dubinsky, Geert D'Haens, David Laharie, Andrew Shim, Byron P. Vaughn Tags: RESEARCH ARTICLE Source Type: research